Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
October 2020, Vol 11, No 5
October 2020, Vol 11, No 5
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
By
Phoebe Starr
ESMO 2020 Highlights
October 2020, Vol 11, No 5
PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and
BRCA1/2
mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and
BRCA1
or
BRCA2
, and to a lesser extent
ATM
mutations, according to the final analysis of the phase 3 PROfound trial.
Read Article
Washington and Public Policy Update During COVID-19
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
What are the practical implications of a flurry of recent healthcare-related actions taken by Congress, the Centers for Medicare & Medicaid Services (CMS), and the White House? In summary, “Some can happen, some will take significant effort, but most are just political grandstanding as we get closer to the election,” said Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Bethesda, MD, and moderator of the mid-August webcast from the Association for Value-Based Cancer Care.
Read Article
Impact of COVID-19 on Economic Trends in Oncology
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
Patients with cancer and cancer treatment dynamics continue to bounce back toward baseline as of late summer 2020, reported experts at the Association for Value-Based Cancer Care August 20 webcast, which focused on economic trends in cancer care during the COVID-19 pandemic.
Read Article
Drug Manufacturers’ Response to the Pandemic
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
Leading global drug manufacturers have been called on to respond to the COVID-19 pandemic in a myriad of ways; several of their executives discussed those responses in a mid-August webcast from the Association for Value-Based Cancer Care.
Read Article
COVID-Related Death Rate Tripled in Patients with Cancer versus the General Population
By
Phoebe Starr
AACR COVID-19 Highlights
,
COVID-19
October 2020, Vol 11, No 5
At the July 2020 AACR virtual meeting on COVID-19 and cancer, Solange Peters, MD, PhD, European Society for Medical Oncology President, and Head, Medical Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, delivered the keynote address, providing an update on the COVID-19 and Cancer Consortium cohort study.
Read Article
Venetoclax plus Azacitidine Combination Improves Overall Survival in Patients with AML
In the Literature
October 2020, Vol 11, No 5
The prognosis of older patients with acute myeloid leukemia (AML) has been poor, even after treatment with a hypomethylating agent. A previous phase 1b study of azacitidine (Vidaza) added to venetoclax (Venclexta) showed promising efficacy and duration of response in treatment-naïve patients with AML who were ineligible for chemotherapy.
Read Article
Selpercatinib, First Treatment for Patients with Thyroid Cancer and RET Mutation, Shows Durable Responses
In the Literature
October 2020, Vol 11, No 5
The safety and durability of responses to multitargeted inhibitors in thyroid cancer are at least partially limited by side effects. In all, 70% of patients with medullary thyroid cancer carry the
RET
mutation;
RET
fusions are rare in other types of thyroid cancer. The efficacy and safety of selective RET inhibition in patients with
RET
-altered thyroid cancer is unknown.
Read Article
Advances in New Therapies Leading to Reduction in Lung Cancer Mortality
In the Literature
October 2020, Vol 11, No 5
The overall mortality for lung cancer has declined in the United States, but little is known about the mortality trends by lung cancer subtype, because death certificates do not record this information. To address this limitation in the data collection, the Surveillance, Epidemiology, and End Results (SEER) program has linked mortality records to incident cancer cases in all cancer types.
Read Article
Capmatinib Shows Substantial Antitumor Activity in Treatment-Naïve Patients with Metastatic NSCLC and MET Exon 14 Mutations
By
Jessica D’Amico
Lung Cancer
October 2020, Vol 11, No 5
Capmatinib (Tabrecta), a selective inhibitor of the mesenchymal-epithelial transition (
MET
) receptor, showed significant antitumor activity in patients with metastatic non–small-cell lung cancer (NSCLC) and gene mutations that lead to MET exon 14 skipping, according to the results of a recently published study.
Read Article
Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma
FDA Approvals, News & Updates
October 2020, Vol 11, No 5
On July 24, 2020, the FDA accelerated the approval of brexucabtagene autoleucel (Tecartus; Kite Pharma), a CAR T-cell therapy, for the treatment of adults with mantle-cell lymphoma (MCL) whose disease has not responded to or has relapsed after other therapies. Brexucabtagene autoleucel is the first gene therapy FDA-approved specifically for the treatment of patients with MCL, a rare type of B-cell non-Hodgkin’s lymphoma.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma